“Amino acids are the building blocks of all cellular function. They signal cells to activate key proteins responsible for a variety of health functions. EBS is the first to discover precise, patented combinations of amino acids that selectively modulate the proteins responsible for maintaining health.”

– Sadasivan Vidyasagar, MD, PhD

Founder and Chairman of the Scientific Board

Deep Space Missions Led to Protein Modulation Breakthrough

A Profound Discovery with Far Reaching Applications

Deep space missions spawned our goal to harness our body’s natural immune and cellular regulation systems to target the proteins that are vital to human health. We found that to truly communicate health and wellness to our cells, we needed to go beyond traditional treatment methodologies.

entrinsic’s technology originated from a $40 million grant sponsored by NASA/BARDA to protect astronauts from the adverse GI effects of ionizing radiation during long duration space travel. Years of research led to the development of our discovery engine, which in turn led to our proven ability to modulate dysregulated proteins associated with specific disease states.

Our Mission

To deliver cost effective, next generation functional ingredients and APIs that transform the way we address health and wellness in self-care and therapeutic categories.

Our History

Nasa Grant

$40M NASA/BARDA/NIH grant to
treat astronaut GI Toxicity

Seed Capital

Investment from EIP

Series A Funding

Investments from EIP & NLDK

Anti-Diarrheal and Cystic Fibrosis
Lung Programs Initiated

Nature Publication

Therapeutic Gastrointestinal effects of amino acid formula

2016

Focus on 3 Verticals

Proof of principle established for beverage,
consumer health, and pharma

2016
2016

Series B

Investment from Johnson & Johnson Innovation
| JJDC & JUNO

2016
2016

Pipeline development through
proof of concept

Initiate clinical trials to support efficacy

2016
2017

21st Century Oncology
Clinical Study

2017
2017

enterade Advanced Oncology
formula commercialized

Clinically proven to reduce the
GI side effects of chemotherapy

2017
2018

Brigham & Women’s
IBSD Study Initiated

2018
2018

Dana-Farber Cancer Institute Phase II Clinical Study

2018
2019

Beverage Subsidiary Established

to focus on functional beverages

2019
2019

UK Phase II Clinical NET Study

2019
2019

US Patent Number 10,322,109 Granted

Composition of matter & methods of use for 2 up to 9 AAs

2019
2019

Series B1 Funding Received

2019
2020

Beverage Deal Closed

with leading global beverage company

2020
2020

Journal of Nutrition Publication

Amino acid formula restores barrier function

2020
2020

CPG Deal

Focused on adult category

2020
Entrinsic Bioscience